Search Results - "Messmann, Richard"

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer by Sartor, Oliver, de Bono, Johann, Chi, Kim N, Fizazi, Karim, Herrmann, Ken, Rahbar, Kambiz, Tagawa, Scott T, Nordquist, Luke T, Vaishampayan, Nitin, El-Haddad, Ghassan, Park, Chandler H, Beer, Tomasz M, Armour, Alison, Pérez-Contreras, Wendy J, DeSilvio, Michelle, Kpamegan, Euloge, Gericke, Germo, Messmann, Richard A, Morris, Michael J, Krause, Bernd J

“…Guiding the beta-emitting isotope lutetium-177 to prostate cancer lesions with the prostate-specific membrane antigen–targeted radioligand 177 Lu-PSMA-617 plus…”
Get full text

The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease by Caston, Rachel A., Gampala, Silpa, Armstrong, Lee, Messmann, Richard A., Fishel, Melissa L., Kelley, Mark R.

“…•APE1 protein repairs small base lesions in the DNA base excision repair pathway.•APE1 converts oxidized inactive transcription factors to a reduced and active…”
Get full text

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial by Fizazi, Karim, Herrmann, Ken, Krause, Bernd J, Rahbar, Kambiz, Chi, Kim N, Morris, Michael J, Sartor, Oliver, Tagawa, Scott T, Kendi, Ayse T, Vogelzang, Nicholas, Calais, Jeremie, Nagarajah, James, Wei, Xiao X, Koshkin, Vadim S, Beauregard, Jean-Mathieu, Chang, Brian, Ghouse, Ray, DeSilvio, Michelle, Messmann, Richard A, de Bono, Johann

“…In VISION, the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy lutetium-177 [177Lu]Lu-PSMA-617 (vipivotide tetraxetan) improved…”
Get full text

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer by NAUMANN, R. Wendel, COLEMAN, Robert L, GERSH, Robert H, TENERIELLO, Michael G, HARB, Wael A, KONSTANTINOPOULOS, Panagiotis A, PENSON, Richard T, SYMANOWSKI, James T, LOVEJOY, Chandra D, LEAMON, Christopher P, MORGENSTERN, David E, MESSMANN, Richard A, BURGER, Robert A, SAUSVILLE, Edward A, KUTARSKA, Elzbieta, GHAMANDE, Sharad A, GABRAIL, Nashat Y, DEPASQUALE, Stephen E, NOWARA, Elzbieta, GILBERT, Lucy

“…Vintafolide (EC145) is a folic acid-desacetylvinblastine conjugate that binds to the folate receptor (FR), which is expressed on the majority of epithelial…”
Get full text

Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic by Shah, Fenil, Logsdon, Derek, Messmann, Richard A., Fehrenbacher, Jill C., Fishel, Melissa L., Kelley, Mark R.

“…Reduction-oxidation factor 1-apurinic/apyrimidinic endonuclease (Ref-1/APE1) is a critical node in tumor cells, both as a redox regulator of transcription…”
Get full text

Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors by LORUSSO, Patricia M, EDELMAN, Martin J, LEAMON, Christopher P, MESSMANN, Richard A, SAUSVILLE, Edward A, BEVER, Susan L, FORMAN, Karen M, PILAT, Maryjo, QUINN, Mary F, JING LI, HEATH, Elisabeth I, MALBURG, Lisa M, KLEIN, Patrick J

“…EC145 (vintafolide), a conjugate of folic acid and the vinca alkaloid desacetylvinblastine hydrazide (DAVLBH), is a ligand for the folate receptor (FR), with…”
Get full text

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors by Tolcher, Anthony W., Rodrigueza, Wendi V., Rasco, Drew W., Patnaik, Amita, Papadopoulos, Kyriakos P., Amaya, Alex, Moore, Timothy D., Gaylor, Shari K., Bisgaier, Charles L., Sooch, Mina P., Woolliscroft, Michael J., Messmann, Richard A.

“…Purpose Maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were assessed in this phase 1 study of PNT2258, a BCL-2-targeted liposomal…”
Get full text

Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330 by Silva, Larissa L., Stratford, Robert E., Messmann, Richard, Kelley, Mark R., Quinney, Sara K.

“…APX3330 ((2E)‐2‐[(4,5‐dimethoxy‐2‐methyl‐3,6‐dioxo‐1,4‐cyclohexadien‐1‐yl)methylene]‐undecanoic acid), a selective inhibitor of APE1/Ref‐1, has been…”
Get full text

Clinical Pharmacokinetics and Exposure-Toxicity Relationship of a Folate-Vinca Alkaloid Conjugate EC145 in Cancer Patients by Li, Jing, Sausville, Edward A., Klein, Patrick J., Morgenstern, David, Leamon, Christopher P., Messmann, Richard A., LoRusso, Patricia

“…The clinical pharmacokinetics and exposure‐toxicity relationship were determined for EC145, a conjugate of folic acid and the Vinca alkaloid…”
Get full text

Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung by Edelman, Martin J, Harb, Wael A, Pal, Sridhar E, Boccia, Ralph V, Kraut, Michael J, Bonomi, Philip, Conley, Barbara A, Rogers, John S, Messmann, Richard A, Garon, Edward B

“…EC145 is a novel folate-receptor targeted agent consisting of a folate molecule linked to a vinca alkaloid. EC20 is a technetium-labeled folate that assesses…”
Get more information

Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications by Leamon, Christopher P, Reddy, Joseph A, Klein, Patrick J, Vlahov, Iontcho R, Dorton, Ryan, Bloomfield, Alicia, Nelson, Melissa, Westrick, Elaine, Parker, Nikki, Bruna, Kristen, Vetzel, Marilynn, Gehrke, Mark, Nicoson, Jeffrey S, Messmann, Richard A, LoRusso, Patricia M, Sausville, Edward A

“…During a phase I trial of EC145 (a folate-targeted vinca alkaloid conjugate), constipation was identified as the dose-limiting toxicity, probably from a…”
Get more information

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide by Rodrigueza, Wendi V., Woolliscroft, Michael J., Ebrahim, Abdul-Shukkur, Forgey, Robert, McGovren, Patrick J., Endert, Gerold, Wagner, Andreas, Holewa, Danielle, Aboukameel, Amro, Gill, Richard D., Bisgaier, Charles L., Messmann, Richard A., Whitehead, Christopher E., Izbicka, Elzbieta, Streeper, Robert, Wick, Michael C., Stiegler, Gabriela, Stein, C. A., Monsma, David, Webb, Craig, Sooch, Mina P., Panzner, Steffen, Mohammad, Ramzi, Goodwin, Neal C., Al-Katib, Ayad

“…PNT100 is a 24-base, chemically unmodified DNA oligonucleotide sequence that is complementary to a region upstream of the BCL-2 gene. Exposure of tumor cells…”
Get full text

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms by SAUSVILLE, Edward A, ARBUCK, Susan G, JING, Xiu-Xian, ROBERGE, Michel, FUSE, Eiichi, KUWABARA, Takashi, SENDEROWICZ, Adrian M, MESSMANN, Richard, HEADLEE, Donna, BAUER, Kenneth S, LUSH, Richard M, MURGO, Anthony, FIGG, William D, LAHUSEN, Tyler, JAKEN, Susan

“…To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine),…”
Get full text

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer by Sartor, Oliver, de Bono, Johann, Chi, Kim N., Fizazi, Karim, Herrmann, Ken, Rahbar, Kambiz, Tagawa, Scott T., Nordquist, Luke T., Vaishampayan, Nitin, El-Haddad, Ghassan, Park, Chandler H., Beer, Tomasz M., Armour, Alison, Pérez-Contreras, Wendy J., DeSilvio, Michelle, Kpamegan, Euloge, Gericke, Germo, Messmann, Richard A., Morris, Michael J., Krause, Bernd J.

Get full text

Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms by TAN, Antoinette R, HEADLEE, Donna, SENDEROWICZ, Adrian M, MESSMANN, Richard, SAUSVILLE, Edward A, ARBUCK, Susan G, MURGO, Anthony J, MELILLO, Giovanni, SUOPING ZHAI, FIGG, William D, SWAIN, Sandra M

“…To define the maximum-tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of the cyclin-dependent kinase inhibitor flavopiridol administered as…”
Get full text

Effects of α1-Acid Glycoprotein on the Clinical Pharmacokinetics of 7-Hydroxystaurosporine by SPARREBOOM, Alex, HUACHEN CHEN, FIGG, William D, ACHARYA, Milin R, SENDEROWICZ, Adrian M, MESSMANN, Richard A, KUWABARA, Takashi, VENZON, David J, MURGO, Anthony J, HEADLEE, Donna, SAUSVILLE, Edward A

“…Objective: UCN-01 (7-hydroxystaurosporine) is a small molecule cyclin-dependent kinase modulator currently under clinical development as an anticancer agent…”
Get full text

Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial by Kuo, Phillip H, Benson, Taylor, Messmann, Richard, Groaning, Michael

Get full text

Flavopiridol-related Proinflammatory Syndrome Is Associated with Induction of Interleukin-6 by MESSMANN, Richard A, ULLMANN, Claudio Dansky, SENDEROWICZ, Adrian M, LAHUSEN, Tyler, KALEHUA, Audrey, WASFY, Jason, MELILLO, Giovanni, DING, Ivan, HEADLEE, Donna, FIGG, William D, SAUSVILLE, Edward A

“…Background: Flavopiridol is a flavonoid with antiproliferative effects mediated, in part, by inhibition of cyclin-dependent kinases. Clinical manifestations in…”
Get full text

The Toxicity of Deglycosylated Ricin A Chain-containing Immunotoxins in Patients with Non-Hodgkin’s Lymphoma Is Exacerbated by Prior Radiotherapy: A Retrospective Analysis of Patients in Five Clinical Trials by SCHINDLER, John, SAUSVILLE, Edward, MESSMANN, Richard, UHR, Jonathan W, VITETTA, Ellen S

“…A retrospective analysis of 102 patients with relapsed, non-Hodgkin’s lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five…”
Get full text

Novel first-in-class small molecule targeting APE1/Ref-1 to prevent and treat chemotherapy-induced peripheral neuropathy (CIPN) by Kelley, Mark R., Messmann, Richard Adam, Fehrenbacher, Jill

“…Abstract only 229 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is an acute and chronic debilitating side effect of a number of…”
Get full text